1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Despite great efforts have been made in the prevention and therapy of human immunodeficiency virus (HIV-1) infection, however the difficulty to eradicate latent viral reservoirs together with the emergence of multi-drug-resistant strains require the search for innovative agents, possibly exploiting novel mechanisms of action. In this context, the HIV-1 reverse transcriptase (RT)-associated ribonuclease H (RNase H), which is one of the few HIV-1 encoded enzymatic function still not targeted by any current drug, can be considered as an appealing target. In this work, we repurposed in-house anti-influenza derivatives based on the 1,2,4-triazolo[1,5-a]-pyrimidine (TZP) scaffold for their ability to inhibit HIV-1 RNase H function. Based on the results, a successive multi-step structural exploration around the TZP core was performed leading to identify catechol derivatives that inhibited RNase H in the low micromolar range without showing RT-associated polymerase inhibitory activity. The antiviral evaluation of the compounds in the MT4 cells showed any activity against HIV-1 (IIIB strain). Molecular modelling and mutagenesis analysis suggested key interactions with an unexplored allosteric site providing insights for the future optimization of this class of RNase H inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Co-crystal structure of compound 1 (magenta) bound to HIV-1 RT (PDB ID: 2I5J) [17]. Chemical structures of the allosteric RNHIs 1 [17], 2 [18], 3 [19,20], 4 [21], 5 [22,24], 6 [23,24], 7 [25], 8 [27], 9 [28], and 10 [29] reported so far and their predicted allosteric binding sites are also indicated. The IC50 value represents the compound concentration that reduces the HIV-1 RT-associated RNase H activity by 50% (HIV-1 RNase H) or the HIV-1 RT-associated RDDP activity by 50% (HIV-1 RDDP); the EC50 value represents the compound concentration that inhibits HIV-1 replication by 50%; The CC50 value represents the compound concentration that inhibits cell growth by 50%; n.d. indicates not determined value. Yellow spheres, polymerase catalytic site; red spheres, RNase H catalytic site.](https://figures.cochat.ai/paper-figures/5545a7836f924202b05b8057cb8bda80/1-2-4-triazolo-1-5-a-pyrimidines-as-a-novel-class-of-inhibitors-of-the-hiv-1-figure-1.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, NNRTIs were found to modulate RNH activity upon recognition of the NNRTI binding site in the polymerase domain [101-103].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [102]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further, mutagenesis studies and hydrogen-exchange experiments indicate a long-range structural change at the RNH domain upon NNRTI interaction in the polymerase domain [102,104].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [102]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Chemistry: Chemical con artists foil drug discovery
Baell, J., & Walters, M. A. (2014) · Nature · doi:10.1038/513481a · Cited by 1,043
Volkamer, A., Kuhn, D., Rippmann, F., & Rarey, M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts310 · Cited by 613
Baell, J. B. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00947 · Cited by 539
Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H., & Arnold, E. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.071 · Cited by 535
Pannecouque, C., Daelemans, D., & De Clercq, E. (2008) · Nature Protocols · doi:10.1038/nprot.2007.517 · Cited by 353
Self-citationThe structural basis of allosteric regulation in proteins
Laskowski, R. A., Gerick, F., & Thornton, J. M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.019 · Cited by 229
Cited by
Recent Advances in 1,2,4‐Triazole Scaffolds as Antiviral Agents
El‐Sebaey, S. A. (2020) · ChemistrySelect · doi:10.1002/slct.202002830 · Cited by 103
Pismataro, M. C., Felicetti, T., Bertagnin, C., Nizi, M. G., Bonomini, A., Barreca, M. L., Cecchetti, V., Jochmans, D., Jonghe, S. D., Neyts, J. H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113494 · Cited by 35
Self-citationEl-Sayed, M. K. F., El-Shahawi, M. M., Ali, Y. M., Abdel-Haleem, D. R., & El‐Azm, F. S. M. A. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106258 · Cited by 28
Recent Trends in Enzyme Inhibition and Activation in Drug Design
Geronikaki, A. A. (2020) · Molecules · doi:10.3390/molecules26010017 · Cited by 25
Yu, G.-X., Hu, Y., Zhang, W.-X., Tian, X.-Y., Zhang, S., Zhang, Y., Yuan, S., & Song, J. (2022) · Molecules · doi:10.3390/molecules27154996 · Cited by 24
Metadata
- Authors
- Desantis, J., Massari, S., Corona, A., Astolfi, A., Sabatini, S., Manfroni, G., Palazzotti, D., Cecchetti, V., Pannecouque, C., Tramontano, E., & Tabarrini, O.
- Affiliations
- University of Perugia (IT)
- University of Cagliari (IT)
- Rega Institute for Medical Research (BE)
- Corresponding author
- Tabarrini, Oriana
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-03-05
- Volume
- 25
- Issue
- 5
- Pages
- 1183
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7179434
- OpenAlex
- W3009905010
- Semantic Scholar
- 84b27c68ed6ac256bf297df085f26505aa16fd9a
- Cited by
- 29
- References
- 55
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 3
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- 1,2,4-triazolo[1,5-a]pyrimidines, RNase H inhibitors, antiviral drug repurposing, catechol derivatives, allosteric inhibition, MT-4 cells, molecular modeling, mutagenesis
- MeSH terms
- Binding Sites, Enzyme Activation, Humans, Molecular Conformation, Protein Binding, Pyrimidines, Structure-Activity Relationship, Drug Design, Molecular Structure, Ribonuclease H, Reverse Transcriptase Inhibitors, HIV Reverse Transcriptase, Molecular Dynamics Simulation, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. https://app.cochat.ai/papers/10.3390/molecules25051183
- The paper
- Desantis, J., Massari, S., Corona, A., Astolfi, A., Sabatini, S., Manfroni, G., Palazzotti, D., Cecchetti, V., Pannecouque, C., Tramontano, E., & Tabarrini, O. (2020). 1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Molecules. https://doi.org/10.3390/molecules25051183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.